As previously announced, AegirBio AB, a leading innovator in saliva-based diagnostics solutions, has received a phase 1 award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program for an accessibility project for multiplex testing.

Today, AegirBio has received funds of $239,547. This award, totaling up to $1.2 million, enables AegirBio AB to commence work towards their continued pursuit of advancements in the field of at-home self-testing.

"We are honored to have received the first installment of the RADx Tech award," said Marco Witteveen, CEO at AegirBioAB. "We are developing a cutting-edge at-home diagnostic platform and a suite of tests that target the digital health market, with a focus on making testing accessible and affordable. This initiative reflects the company’s dedication to revolutionizing healthcare delivery and enhancing patient outcomes.” 

This project has been funded in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.

About Aegirbio

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com

The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | info@eminova.se

Related link:
Cision